【Abstract】 Objective To investigate the effect of butylphthalide soft capsule combined with edaravone on neurological deficit and plasma fibrinogen in patients with acute cerebral infarction. Methods〓Between January 2016 and December 2017, 94 acute cerebral infarction patients admitted to our hospital were selected and divided into control group and observation group according to different treatment plans. Patients in the control group were treated with routine medical therapy and edaravone. Based on this, the observation group received the butylphthalide soft capsule. The changes of neurological deficits, clinical efficacy, plasma fibrinogen (FIB), hemorheology, blood lipids, serum neuronspecific enolase (NSE), interleukin6 (IL6), tumor necrosis factorα (TNFα), quality of life and adverse reactions were compared between the two groups before and after treatment. Results The total effective rate in the observation group was significantly higher than that in the control group (9574% vs 7659%, P＜005). The FIB, plasma viscosity, low / high notch viscosity of the whole blood, LDL, TC, HDL of the two groups had no significant difference before treatment. The above levels except HDL were all decreased after treatment (P＜005). Both the increasing level and decreasing level were more significant in the observation group than in the control group (P＜005). The decreasing level of the NIHSS score in the observation group was more obvious than in the control group (P＜0001). The decrease of serum NSE, IL6 and TNFα in the observation group was significantly greater than that in the control group (P＜005). The scores of RP, BP, MH, RE, VT and SF in the observation group were significantly higher than those in the control group (P＜005). No serious adverse reactions occurred in both groups of patients during the treatment. Conclusion The butylphthalide soft capsule combined with edaravone is an effective and safe way to ameliorate the neurological deficit degree, plasma FIB index and quality of life for acute cerebral infarction patients.